News
WGS
69.82
+1.67%
1.15
WGS Investors Have Opportunity to Lead GeneDx Holdings Corp. Securities Fraud Lawsuit
PR Newswire · 21h ago
GeneDx Holdings Securities Fraud Class Action Result of Acquisition Performance Misrepresentations and 49% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC
PR Newswire · 1d ago
GeneDx Holdings (WGS) Names Mark Gardner President, Is It Still Below Fair Value?
Simply Wall St · 2d ago
GeneDx Holdings Corp. (WGS) Investors: August 3, 2026, Deadline in Securities Fraud Class Action Lawsuit
PR Newswire · 3d ago
GeneDx Holdings (WGS) Faces Securities Class Action After 49% Drop, 94% Write-off Related to Fabric Genomics Acquisition - HBSS
PR Newswire · 3d ago
Robbins LLP Urges WGS Stockholders Who Lost Money Investing in GeneDx Holdings Corp. to Contact the Firm for Information About Leading the Class Action
PR Newswire · 3d ago
10 small-cap U.S. healthcare stocks with the weakest momentum grades
Seeking Alpha · 4d ago
What a $227,000 GeneDx Insider Sale Means as Revenue Climbs 17%
The Motley Fool · 4d ago
GeneDx Holdings Is Maintained at Overweight by Piper Sandler
Dow Jones · 5d ago
GeneDx Holdings Price Target Raised to $63.00/Share From $50.00 by Piper Sandler
Dow Jones · 5d ago
Piper Sandler Maintains Overweight on GeneDx Holdings, Raises Price Target to $63
Benzinga · 5d ago
GeneDx Holdings (WGS) Faces Securities Class Action After 49% Drop, 94% Write-off Related to Fabric Genomics Acquisition - HBSS
PR Newswire · 5d ago
GeneDx Shareholders Back Director, Auditor and Pay Plans
TipRanks · 5d ago
GeneDx holds annual shareholder meeting
PUBT · 5d ago
GeneDx price target raised to $63 from $50 at Piper Sandler
TipRanks · 5d ago
WGS Investors Have Opportunity to Lead GeneDx Holdings Corp. Securities Fraud Lawsuit
PR Newswire · 5d ago
U.S. RESEARCH ROUNDUP-Apogee Therapeutics, GE Healthcare, Synopsys
Reuters · 5d ago
GENEDX HOLDINGS CORP <WGS.O>: PIPER SANDLER RAISES TARGET PRICE TO $63 FROM $50
Reuters · 5d ago
GeneDx: Why I Think The Selloff Went Too Far
Seeking Alpha · 6d ago
WGS INVESTOR NOTICE: GeneDx Holdings Corp. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit
PR Newswire · 6d ago
More
Webull provides a variety of real-time WGS stock news. You can receive the latest news about GeneDx Holdings Corp through multiple platforms. This information may help you make smarter investment decisions.
About WGS
GeneDx Holdings Corp. is a genomics company. The Company operates, through its subsidiary, GeneDx, LLC, which is focused on exome and genome tests that translate complex genomic data into clinical answers that unlock personalized health plans, accelerate drug discovery, and improve health system efficiencies. It operates through GeneDx segment, which primarily provides pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing and, to a lesser extent, data and information services. Exome sequencing test options include XomeDx, XomeDx Plus, and XomeDxXpress. GeneDx genome sequencing evaluates the protein-coding and non-coding regions of an individual’s nuclear genome. GeneDx genome sequencing test options include GenomeSeqDx and GenomeXpress. It offers a menu of targeted variant testing options to meet the needs of families and healthcare providers. Its subsidiary, Fabric Genomics, Inc., specializes in artificial intelligence-powered genomic interpretation.